Healthcare Industry News:  cataract 

Devices Surgery Ophthalmology

 News Release - May 5, 2016

Valeant Pharmaceuticals Announces Collaboration Between Bausch & Lomb And IBM

Developing First-of-its Kind App for cataract Surgeons on IBM Cloud

LAVAL, Quebec, May 5, 2016 -- (Healthcare Sales & Marketing Network) -- Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Bausch & Lomb, a leading global eye health company, and IBM (IBM) today announced a collaboration to develop the first app of its kind for iPhone and iPad to assist surgeons who perform cataract surgery. The innovative app will help surgeons streamline their workflow by delivering patient information and clinical insights as well as intraocular lens (IOL) selection guidance on a single digital platform at the point of care.

The app will be designed to electronically manage patient data across iPhone and iPad while hosting health-related data on IBM Cloud -- a secure, cloud-based environment -- and relaying informed, customized IOL options to surgeons that they will use to help enhance surgical planning and provide better patient care. The MobileFirst for iOS team, which is part of IBM Global Business Services, will design and develop this custom app for Bausch & Lomb to help drive innovation in healthcare. Bausch & Lomb's vision is to optimize the app to collect data over time, resulting in a cognitive app that applies machine-based learning and predictive analytics to deliver real-time insights to surgeons.

"Improving health outcomes is at the core of our business at Valeant," said Joseph C. Papa, Chairman and Chief Executive Officer of Valeant. "We're excited that Bausch & Lomb and IBM will team up to develop a first-of-its-kind app that takes the best of each business's capabilities and focuses on enhancing critical decision-making for surgeons. This collaboration is a strong reflection of B&L's commitment to the ophthalmology industry and the patients that it serves."

Pilot study testing for the new application is expected to begin in late 2016. For more information regarding the collaboration, visit the Newsroom section at

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at

Forward-looking Statements

This press release contains forward-looking statements. Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes, unless required by law.

Source: Valeant Pharmaceuticals

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.